drugset
drugset / Trial / NCT04582591

Cannabidiol for Prevention of Chemotherapy-induced Peripheral Neuropathy

NCT04582591 ↗

Phase 2 Unknown 54 enrolled Zealand University Hospital University of Copenhagen · collab
NaSingle-groupOpen-labelPrevention

Summary

This protocol describes a phase II trial investigating the efficacy of CBD in paclitaxel- and oxaliplatin-induced peripheral neuropathy. The trial uses multiple assessments such as validated PRO-questionnaires and multifrequency vibrometry.

Timeline

Start
2021-03-03
Primary completion
2022-01-05
Completion
2023-08-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Cannabidiol Other / unclassified 100 mg/ml —

Indications

chemotherapy-induced neuropathy